16 employees
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
2022
$17M
from 4 investors over 4 rounds
LTZ Therapeutics raised $10M on May 31, 2023
Investors: K2 Venture Capital and Qiming Venture Partners
LTZ Therapeutics raised $17M on April 7, 2022
Investors: Qiming Venture Partners and Tigermed